Skip to main content
    P

    Prothena Corporation plc (PRTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.97
    -0.19 (-2.33%)

    Market Cap: $419.01M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Prothena Corporation plc (PRTA) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Prothena Corporation (PRTA) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Prothena Corporation reported EPS of -$0.32, above the -$0.38 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    +16.56%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.09
    Range-$0.38 - $0.79
    8 analysts
    Revenue Consensus
    $15.10M
    RangeN/A
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.41
    Range-$0.41 - -$0.41
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.36-13.9%
    60d ago-$0.36-13.9%
    30d ago-$0.36-13.9%
    7d ago-$0.36-13.9%
    Current-$0.41
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    PRTA has an expected report date of Feb 17, 2027.

    PRTA Earnings Call

    The latest PRTA earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PRTA beat 19, missed 20 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $620000, down 74.4% from $2.42M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.32-$0.38-$0.38 - -$0.22+15.79%BeatN/A21 up, 0 downNov 5, 2026$620000
    Jun 30, 2026-$0.32-$0.39N/A+17.95%BeatN/A21 up, 0 downAug 6, 2026$1.01M
    Mar 31, 2026$0.68-$0.30-$0.38 - -$0.23+326.67%BeatN/A21 up, 0 downMay 7, 2026$51.08M
    Dec 31, 2025-$0.46-$0.46-$0.58 - -$0.390.00%In lineN/A31 up, 1 downFeb 19, 2026$21000
    Sep 30, 2025-$0.67-$0.54-$0.64 - -$0.44-24.07%MissN/A40 up, 0 downNov 6, 2025$2.42M
    Jun 30, 2025-$1.73-$1.79-$2.57 - -$1.33+3.35%Beat-241.8%30 up, 3 downAug 4, 2025$4.42M
    Mar 31, 2025-$1.12-$1.03-$1.16 - -$0.57-8.74%MissN/A62 up, 0 downMay 8, 2025$2.83M
    Dec 31, 2024-$1.08-$1.04-$1.22 - -$0.58-3.85%MissN/A91 up, 0 downFeb 20, 2025$2.12M
    Sep 30, 2024-$1.10-$1.18-$1.28 - -$1.03+6.78%Beat-389.5%80 up, 0 downNov 12, 2024$970000
    Jun 30, 2024$1.22-$1.03-$1.38 - $0.32+218.45%BeatN/A91 up, 0 downAug 8, 2024$132.01M
    Mar 31, 2024-$1.34-$1.22-$1.42 - -$1.09-9.84%MissN/A80 up, 0 downMay 8, 2024$50000
    Dec 31, 2023-$1.26-$1.19-$1.46 - -$0.87-5.88%Miss-1150.0%90 up, 0 downFeb 15, 2024$316000
    Sep 30, 2023$0.38-$0.34-$1.39 - $0.03+211.76%BeatN/A90 up, 0 downNov 2, 2023$84.87M
    Jun 30, 2023-$1.03-$0.97-$1.21 - -$0.12-6.19%MissN/A100 up, 0 downAug 3, 2023$4.02M
    Mar 31, 2023-$0.89-$0.84-$1.19 - -$0.12-5.95%MissN/A80 up, 0 downMay 4, 2023$2.17M
    Dec 31, 2022$0.12-$0.47-$1.14 - -$0.02+125.53%BeatN/A100 up, 0 downFeb 23, 2023$49.92M
    Sep 30, 2022-$0.97-$0.62-$1.13 - $0.20-56.45%Miss-145.5%90 up, 0 downNov 3, 2022$1.52M
    Jun 30, 2022-$0.88-$0.53N/A-66.04%Miss-251.7%N/A1 up, 0 downAug 8, 2022$1.31M
    Mar 31, 2022-$0.78-$0.64-$0.94 - $0.03-21.88%MissN/A60 up, 1 downMay 5, 2022$1.15M
    Dec 31, 2021-$0.71-$0.44-$0.84 - $0.20-61.36%MissN/A70 up, 0 downFeb 17, 2022$1.17M
    Sep 30, 2021$2.13$2.24$2.00 - $2.50-4.91%MissN/A5N/ANov 4, 2021$139.17M
    Jun 30, 2021$0.58$1.17$0.28 - $2.41-50.43%MissN/A8N/AAug 5, 2021$60.07M
    Mar 31, 2021-$0.91-$0.49-$0.82 - $0.73-85.71%MissN/A6N/AMay 11, 2021$160000
    Dec 31, 2020-$0.77-$0.74-$0.92 - -$0.55-4.05%MissN/A7N/AFeb 11, 2021$360000
    Sep 30, 2020-$0.77-$0.65-$0.70 - -$0.59-18.46%MissN/A6N/ANov 4, 2020$157000
    Jun 30, 2020-$0.66-$0.59-$0.64 - -$0.55-11.86%MissN/A6N/AAug 6, 2020$195000
    Mar 31, 2020-$0.59-$0.56-$0.64 - -$0.54-5.36%MissN/A7N/AMay 6, 2020$141000
    Dec 31, 2019-$0.54-$0.55-$0.68 - -$0.49+1.82%BeatN/A6N/AFeb 12, 2020$256000
    Sep 30, 2019-$0.49-$0.46-$0.60 - -$0.39-6.52%MissN/A6N/ANov 5, 2019$205000
    Jun 30, 2019-$0.40-$0.58-$0.59 - -$0.55+31.03%BeatN/A5N/AAug 6, 2019$167000
    Mar 31, 2019-$0.52-$0.59-$0.81 - -$0.51+11.86%BeatN/A6N/AMay 7, 2019$186000
    Dec 31, 2018-$0.60-$0.89-$1.27 - -$0.60+32.58%BeatN/A7N/AFeb 14, 2019$194000
    Sep 30, 2018-$0.70-$0.82-$1.36 - -$0.35+14.63%BeatN/A8N/ANov 6, 2018$255000
    Jun 30, 2018-$1.00-$1.24-$1.63 - -$0.55+19.35%BeatN/A8N/AAug 7, 2018$279000
    Mar 31, 2018-$1.26-$1.34-$1.59 - $1.22+5.97%BeatN/A10N/AMay 8, 2018$227000
    Dec 31, 2017-$1.24-$1.48-$1.61 - -$1.36+16.22%BeatN/A11N/AFeb 14, 2018$229000
    Sep 30, 2017-$1.37-$1.46-$1.54 - -$1.02+6.16%BeatN/A11N/ANov 7, 2017$219000
    Jun 30, 2017-$0.46-$0.81-$1.49 - -$0.50+43.21%BeatN/A10N/AAug 8, 2017$26.81M
    Mar 31, 2017-$0.99-$1.36N/A+27.21%BeatN/AN/AN/AMay 9, 2017$259000
    Dec 31, 2016-$1.41-$1.21N/A-16.53%MissN/AN/AN/AFeb 14, 2017$171000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.98, after -$2.30 the year before. It was -$4.66 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.98N/A
    Dec 31, 2024-$2.30N/A
    Dec 31, 2023-$2.80N/A
    Dec 31, 2022-$2.51-330.3%
    Dec 31, 2021$1.09N/A
    Dec 31, 2020-$2.79N/A
    Dec 31, 2019-$1.95N/A
    Dec 31, 2018-$3.56N/A
    Dec 31, 2017-$4.06N/A
    Dec 31, 2016-$4.66N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 6,900 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20256,93112
    2024Q4Dec 31, 20247,75815

    2025Q4 Earnings Call

    Opening remarks

    Mark Johnson Vice President, Head of Investor Relations Thank you, operator. Good afternoon, everyone, and welcome to today's call to review Prothena's business progress, fourth quarter and full year 2025 financial results, and 2026 financial guidance. Please review the press release we issued earlier today, which is available on our website at prothena.com and is also attached to a Form 8-K filed today with the SEC. In addition, we are using supplemental slides, which are available on our Investors website, Events & Presentations section. On today's call, Dr. Gene Kinney, our President and Executive Officer, will provide opening remarks, including an overview on Prothena's corporate strategy. Chad Swanson, our Chief Development Officer, will provide an update on our ongoing partnered clinical programs. Then Phil Dolan, our Vice President and Head of Discovery Research, will provide an update on our active preclinical programs. Tran Nguyen, our Chief Strategy Officer and Chief Financial Officer, will then discuss our 2025 financial results and 2026 financial guidance before turning it back to Gene for closing remarks, at which point, we will open up the call for a Q&A session. Brandon Smith, our Chief Operating Officer, will also be available during the Q&A session. Before we begin, I would like to remind you that during today's presentation, we will be making forward-looking statements that are subject to certain risks, uncertainties, and other factors that could cause actual results to differ materially from those referred to in any of the forward-looking statements. For a discussion of these risks and uncertainties associated with our forward-looking statements, please see our press release issued today as well as our most recent filings with the SEC and our annual report on Form 10-K to be filed with the SEC for our fiscal year 2025. We disclaim any obligation to update our forward-looking statements. With that, I'd like to turn the call over to Gene.

    Gene G. Kinney President and Executive Officer Thank you, Mark, and thank you all for joining us today. Let's begin on Slide 5. In 2025, we saw significant progress with our clinical pipeline where 2 of our partner programs, prasinezumab and coramitug, advanced into Phase III clinical trials. Roche advanced prasinezumab into the Phase III PARAISO trial, evaluating 900 participants with early Parkinson's disease. This decision was informed by results from 2 Phase II clinical trials that both demonstrated consistent slowing of disease progression. Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial, evaluating 1,280 patients with amyloid transthyretin cardiomyopathy or ATTR-CM. This decision was informed by results from their Phase II trial demonstrating positive NT-proBNP and echocardiogram changes as well as directional observation of benefit in the 6-minute walk test.

    Frequently Asked Questions About PRTA

    When is Prothena Corporation's next earnings date?

    Prothena Corporation's next earnings report is expected for Feb 17, 2027.

    Did PRTA beat earnings estimates last quarter?

    Yes. Prothena Corporation reported EPS of -$0.32 for the quarter ended Sep 30, 2026, above the -$0.38 estimate, a 15.79% surprise.

    What EPS do analysts expect from PRTA next quarter?

    The consensus EPS estimate for Prothena Corporation for the quarter ending Dec 31, 2026 is -$0.09 from 8 analysts, with estimates from -$0.38 to $0.79.

    How often does PRTA beat earnings estimates?

    Prothena Corporation beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +40.89%.